Diagnostic value of percutaneous liver biopsy in fever of unkown origin in patients with human immunodeficiency virus infection

Abstract

© 2015, National Institute of Health. All rights reserved. Fever of unknown origin (FUO) poses a major diagnostic challenge in patients infected with human immunodeficiency virus (HIV). In this retrospective study, we sought to assess the clinical utility of percutaneous liver biopsy as a diagnostic aid for FUO in HIV-infected patients and identify the factors associated with a greater likelihood of a positive diagnostic yield form this procedure. A total of 101 HIV-infected patients with FUO, who had undergone percutaneous liver biopsy in an HIV care hospital, served as the study population. The results obtained from percutaneous liver biopsy were categorized into three groups: (i) diagnostic, (ii) helpful, and (iii) not helpful. Diagnostic and helpful results were classified as useful. The mean (SD) age of patients was 37.6 (6.9) years, and the median (interquartile range [IQR]) CD4 count was 18 (3–62) cells/mm³. The median (IQR) duration of fever was 20 (8–30) days. Percutaneous liver biopsy was diagnostic in 51 patients (50.5z), helpful in 12 (11.9z) and not helpful in 38 (37.6z) patients. On multivariate analyses, elevation of serum alkaline phosphatase level (OR 1.27 per one time elevation from the upper normal range; 95z CI, 1.03–1.57; P = 0.023), and fever duration of less than 3 weeks (OR 3.82; 95z CI, 1.03–14.18; P = 0.046) was significantly associated with the likelihood of the biopsy findings being classified as useful. Our study supports the case for percutaneous liver biopsy as a useful diagnostic aid in HIV-infected patients with FUO.